Myeloid Malignancy NGS Panel
Use
The Hematologic Neoplasm Testing by NGS assay is designed to identify somatic mutations in 26 genes frequently mutated in myeloid malignancies. This assay aids in the diagnosis and management of myeloid neoplasms by providing genetic insights into the mutations driving the disease.
Special Instructions
Frozen blood and bone marrow samples are NOT accepted. Extracted DNA: Isolation of nucleic acids for clinical testing must occur in a CLIA-certified laboratory or a laboratory meeting equivalent requirements. Concentration and volume must be provided for all samples.
Limitations
Test cannot be used with frozen blood or bone marrow samples. Samples outside the designated stability periods or improperly labeled may be rejected. The test is limited to detecting mutations in the 26 specified genes, and other genetic aberrations will not be detected.
Methodology
NGS (Targeted)
Biomarkers
Result Turnaround Time
14 days
Related Documents
For more information, please review the documents below
Specimen
Whole Blood
Volume
5mL
Minimum Volume
3mL
Container
EDTA preferred (NaHep accepted)
Storage Instructions
2°C to 8°C
Causes for Rejection
Improper specimen labeling; Insufficient sample volume; Clotted specimen
Stability Requirements
| Temperature | Period |
|---|---|
| Room Temperature | 96 hours |
| Refrigerated | 30 days |
| Frozen | Long-term |